IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE-BC1)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
| Condition | Intervention | Phase |
|---|---|---|
| Malaria | Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants | Phase 3 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Prevention |
| Official Title: | Reducing the Burden of Malaria in HIV-uninfected Pregnant Women and Infants (PROMOTE Birth Cohort 1) |
- Prevalence of placental malaria [ Time Frame: Delivery ]Prevalence of placental malaria based on placental histopathology dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence and by histopathology as a categorical variable based on Rogerson et al criteria.
- Incidence of malaria in pregnant women [ Time Frame: Time at risk will begin at birth and will end when study participants reaches 24 months of age, when the intervention will be stopped, or early study termination (if prior to 24 months of age). ]Incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.
- Incidence of malaria in infants [ Time Frame: Time at risk will begin at birth and will end when study participants reaches 24 months of age or early study termination (if prior to 24 months of age) and at 24 months of age and will end when study participants reaches 36 months of age or termination ]Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days. The study investigators will test the hypotheses that A) infants born to mothers randomized to receive IPTp with 3 dose DP or monthly DP will have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with 3 doses of SP, and, B) infants randomized to receive monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized q 3 monthly DP between 2-24 months of age.
- Placental parasitemia [ Time Frame: Delivery ]Proportion of placental blood samples positive for parasites by microscopy or PCR
- Prevalence of maternal malaria [ Time Frame: Gestational age between 12-20 weeks (at study entry) up to delivery ]Any treatment for malaria while on malaria chemoprevention
- Composite birth outcome [ Time Frame: Delivery ]Congenital malformations, late spontaneous abortion, LBW (<2500g), still birth
- Incidence of adverse events in pregnant women and infants [ Time Frame: For women, starting at the time of their first study drugs approximately gestational age between 12-20 weeks up to one month post-deliver; For infants: from birth up to up to 108 weeks of age ]Adverse events stratified by type, severity score and relationship to study drugs
- Prevalence of anemia in pregnant women and infants [ Time Frame: Women: Gestational age between 12-20 weeks (at study entry) up to delivery; Infants: Birth up to 24 months of age or early study termination ]Proportion of routine hemoglobin measurements < 10 g/dL & < 8 g/dL
- Incidence of complicated malaria in infants [ Time Frame: Birth up to 24 months of age or early study termination ]Any treatment for malaria meeting criteria for severe malaria or danger signs
- Incidence of hospital admissions in infants [ Time Frame: Birth up to 24 months of age or early study termination ]Admission to a hospital for pediatric inpatient care for any reason
- Prevalence of gametocytemia in pregnant women and infants [ Time Frame: Women: Gestational age between 12-20 weeks (at study entry) up to delivery; Infants: Birth up to 24 months of age or early study termination ]Proportion of routine blood smears positive for gametocytes
- Prevalence of asymptomatic parasitemia in pregnant women and infants [ Time Frame: Women: Gestational age between 12-20 weeks (at study entry) up to delivery; Infants: Birth up to 24 months of age or early study termination ]Proportion of routine monthly samples positive for parasites by PCR. Proportion of routine samples (PCR or blood smears) positive for asexual parasites.
| Enrollment: | 300 |
| Study Start Date: | June 2014 |
| Estimated Study Completion Date: | June 2018 |
| Estimated Primary Completion Date: | June 2018 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Active Comparator: 3 dose SP pregnancy / 3 monthly DP infancy
Women will be given SP (3 full strength tabs, 500 mg/25 mg) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug. |
Drug: 3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy
Other Name: Kamsidar (KPI)
Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Other Name: Duo-Cotexin (Holley-Cotec)
|
|
Active Comparator: 3 dose DP pregnancy / 3 monthly DP infancy
Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug. |
Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Other Name: Duo-Cotexin (Holley-Cotec)
Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Other Name: Duo-Cotexin (Holley-Cotec)
|
|
Active Comparator: 3 dose DP pregnancy / monthly DP infancy
Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) 3 times during pregnancy at 20, 28, and 36 weeks gestational age. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. Infants will be given DP (once a day for 3 consecutive days using weight-based guidelines) every 4 weeks between 8 and 104 weeks of age. |
Drug: 3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Other Name: Duo-Cotexin (Holley-Cotec)
Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants
Other Name: Duo-Cotexin (Holley-Cotec)
|
|
Active Comparator: monthly DP pregnancy / 3 monthly DP infancy
Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. Infants will be given DP (once a day for 3 consecutive days) every 12 weeks between 8 and 104 weeks of age. Infants randomized to receive DP every 12 weeks will receive placebo mimicking the dosing of DP every 4 weeks when they are not receiving study drug. |
Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Other Name: Duo-Cotexin (Holley-Cotec)
Drug: 3-monthly dihydroartemisinin-piperaquine (DP) for infants
Other Name: Duo-Cotexin (Holley-Cotec)
|
|
Active Comparator: monthly DP pregnancy / monthly DP infancy
Women will be given DP (3 full strength tabs, 40 mg/320 mg, given once a day for 3 consecutive days) every 4 weeks during pregnancy. In addition, placebos will be used to mimic the identical dosing strategy such that every 4 weeks women will receive two pills on day 1 (SP and placebo, DP and placebo, or two placebos) followed by one pill on days 2 and 3 (DP or placebo). Two placebos will be used, one that mimics the appearance of SP and one that mimics the appearance of DP. Infants will be given DP (once a day for 3 consecutive days) every 4 weeks between 8 and 104 weeks of age. |
Drug: Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy
Other Name: Duo-Cotexin (Holley-Cotec)
Drug: Monthly dihydroartemisinin-piperaquine (DP) for infants
Other Name: Duo-Cotexin (Holley-Cotec)
|
Detailed Description:
Pregnant women will be scheduled to be seen in the clinic every 4 weeks during their pregnancy and 6 weeks following delivery. In addition, pregnant women will be instructed to come to the study clinic for all their medical care and avoid the use of any outside medications. Children will be scheduled to be seen in the clinic every 4 weeks and parents /guardians of children will be instructed to bring their child to the study clinic for all medical care and avoid the use of any outside medications. The study clinic will remain open 7 days a week from 8 a.m. to 5 p.m.
Each time a study participant is seen in the clinic a standardized history and physical exam will be performed. Patients who are febrile (tympanic temperature > 3 8.0˚C) or report history of fever in the past 24 hours will have blood obtained by finger prick for a thick blood smear. If the thick blood smear is positive, the patient will be diagnosed with malaria. If the thick blood smear is negative, the patient will be managed by study physicians for a non-malarial febrile illness. If the patient is afebrile and does not report a recent fever, a thick blood smear will not be obtained, except when following routine testing schedules.
Routine assessments will be done in the clinic every 4 weeks for both pregnant women and children. Pregnant women and children will receive standards of care as designated in the Uganda MOH guidelines. Routine care in children will use Integrated Management of Childhood Illness (IMCI) guidelines. During routine assessments subjects will be asked about visits to outside health facilities and the use of any medications outside the study protocol. Standardized assessment of adherence will also be done for study drugs administered at home and Insecticide Treated Net use. A routine history and physical exam will be performed using a standardized clinical assessment form. Blood will be collected by finger prick for thick smear, collection of plasma for PK studies, and filter paper samples. Phlebotomy for routine laboratory tests (CBC and ALT) to monitor for potential adverse events from study medications and for immunology studies will be performed every 8 weeks in pregnant women and every 16 weeks in children. Non malaria screening will also include stool ova and parasite examination, circulating filarial antigens (by ICT card for Wucheria), and blood smear for microfilaremia (including Mansonella perstans) using Knott's technique. For pregnant women and children 2-24 months of age, study drugs will be administered at the time of each routine visit.
Eligibility| Ages Eligible for Study: | 16 Years and older (Child, Adult, Senior) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Pregnancy confirmed by positive urine pregnancy test or intrauterine pregnancy by ultrasound
- Estimated gestational age between 12-20 weeks
- Confirmed to be HIV uninfected by rapid test
- 16 years of age or older
- Residency within 30km of the study clinic
- Provision of informed consent by the pregnant woman for herself and her unborn child
- Agreement to come to the study clinic for any febrile episode or other illness and avoid medications given outside the study protocol
- Plan to deliver in the hospital
Exclusion Criteria:
- History of serious adverse event to SP or DP
- Active medical problem requiring inpatient evaluation at the time of screening
- Intention of moving more than 30km from the study clinic
- Chronic medical condition requiring frequent medical attention
- Prior SP preventive therapy or any other antimalarial therapy during this pregnancy
- Early or active labor (documented by cervical change with uterine contractions)
Contacts and LocationsPlease refer to this study by its ClinicalTrials.gov identifier: NCT02163447
| Uganda | |
| IDRC Research Clinic -Tororo District Hospital | |
| Tororo, Uganda | |
| Principal Investigator: | Grant Dorsey, MD, PhD | University of California, San Francisco |
| Principal Investigator: | Diane V Havlir, MD | University of California, San Francisco |
| Principal Investigator: | Moses Kamya, MBChB, MMed, PhD | Makerere University; Infectious Diseases Research Collaboration |
More Information
Additional Information:
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Grant Dorsey, M.D, Ph.D., Professor, University of California, San Francisco |
| ClinicalTrials.gov Identifier: | NCT02163447 History of Changes |
| Other Study ID Numbers: |
PROMOTE-BC1 P01HD059454 ( US NIH Grant/Contract Award Number ) |
| Study First Received: | June 5, 2014 |
| Last Updated: | April 2, 2016 |
Keywords provided by Grant Dorsey, M.D, Ph.D., University of California, San Francisco:
|
Chemoprevention Malaria Uganda Sulfadoxine-pyrimethamine Dihydroartemisinin-piperaquine |
Additional relevant MeSH terms:
|
Malaria Protozoan Infections Parasitic Diseases Pyrimethamine Piperaquine Sulfadoxine Dihydroartemisinin Artemisinins Fanasil, pyrimethamine drug combination |
Antimalarials Antiprotozoal Agents Antiparasitic Agents Anti-Infective Agents Folic Acid Antagonists Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-Infective Agents, Urinary Renal Agents |
ClinicalTrials.gov processed this record on June 26, 2017